

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Angelo GUGLIELMOTTI, et al.

SERIAL NO: New U.S. PCT Application Based on PCT/EP04/07633

GAU:

FILED: Herewith

EXAMINER:

FOR: USE OF 2H-[1,3]-OXAZINO [3, 2-A] INDOLE DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).


CERTIFICATION

- Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C._____
Norman F. Oblon
Registration No. 24,618

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)Surinder Sachar
Registration No. 34,423

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT			ATTY DOCKET NO. 281760US0PCT		SERIAL NO. New U.S. PCT Application Based on PCT/EP04/07633		
			APPLICANT Angelo GUGLIELMOTTI, et al.				
			FILING DATE Herewith		GROUP		
			U.S. PATENT DOCUMENTS				
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA	5 817 676	10/06/98	CATLOW et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION		
	AB	0 630 376	12/28/94	EP	YES	NO	
	AC	0 884 319	12/16/98	EP		NO	
	AD	93/06108	04/01/93	WO		NO	
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AE	HOUGHTON et al. "5-HT4 receptor antagonism in irritable bowel syndrome: effect of SB-207266-A on rectal sensitivity and small bowel transit", Aliment Pharmacol Ther, vol. 13, pages 1437-1444 1999					
	AF	DOAK et al. "Formalin-Induced Nociceptive Behavior and Edema: Involvement of Multiple Peripheral 5-Hydroxytryptamine Receptor Subtypes", Neuroscience, vol. 80, pages 939-949 1997					
	AG	DONAHUE et al. "Electrolytic lesion of the anterior cingulate cortex decreases inflammatory, but not neuropathic nociceptive behavior in rats", Brain Research, vol. 897, pages 131-138 2001					
	AH	BEERS et al. "The Merck Manual of Diagnosis and Therapy", Merck Research Laboratories, page 1371-1372, 17 th edition 1999					
	AI	WEI et al. "Influence of Two Serotonin Receptor Antagonists in Neuropathic Rats", Pfluegers Archiv European Journal of Physiology, vol. 443, no. supplement 1, page S181 2002					
	AJ	ASHBURN et al. "Management of chronic pain", The Lancet, vol. 353, 1865-1869 1999					
	AK	WOOLF et al. "Neuropathic pain: aetiology, symptoms, mechanisms, and management", The Lancet, vol. 353, pages 1959-1964 1999					
	AL	SCHOLZ et al. "Can we conquer pain?", Nature Neuroscience Supplement, vol. 5, pages 1062-1067 2002					
	AM	SELTZER et al. "A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury", Pain, vol. 43, pages 205-218 1990					
	AN	BENNETT et al. "A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man", Pain, vol. 33, pages 87-107 1988					
	AO	COURTEIX et al. "Streptozocin-induced diabetic rats: behavioural evidence for a model of chronic pain", Pain, vol. 53, pages 81-88 1993					
	AP	BANNON et al. "ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain", Brain Research, vol. 801, pages 158-163 1998				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner				Date Considered			

10/560836
IAP20 Rec'd AT CWO 15 DEC 2005

New U.S. PCT Application Based on PCT/EP04/07633
Docket No.: 281760US0PCT

STATEMENT OF RELEVANCY

- 1) References AA-AI have been cited in the International Search Report. Copies of these references are being submitted herewith only when not automatically provided by the International Searching Authority.
- 2) References _____ have been cited in the corresponding _____ Search Report. A copy of these references is being submitted herewith.
- 3) References AJ-AP are discussed in the specification. A copy of these references is being submitted here with.
- 4) References _____ are additional prior art known to Applicant. A copy of these references is being submitted herewith.